Patents by Inventor Burkhard Enders

Burkhard Enders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5585268
    Abstract: The invention relates to malaria-specific nucleic acid sequences, to the expression products thereof, and to the use thereof. A combination of three of the expression proteins whose nucleic acid sequences were isolated by screening a lambda gt11 gene bank with a monospecific antiserum against the protective 41 kD antigen band from P. falciparum protects Aotus monkeys from a P. falciparum infection in model experiments.
    Type: Grant
    Filed: September 29, 1993
    Date of Patent: December 17, 1996
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Bernhard Knapp, Erika Hundt, Burkhard Enders, Hans K upper
  • Patent number: 5395614
    Abstract: Protective Plasmodium falciparum hybrid proteins which contain part-sequences of the malaria antigens HRPII and SERP, the preparation and use thereof.The invention relates to hybrid proteins composed of part-sequences of the malaria antigens HRPII and SERP. The HRPII sequence has already proven protective in the monkey model (EP-A2-0 315 085), where a C-terminal region of 189 amino acids has been used in the present invention in the same way as in the preceding protection experiment. SERP was identified with the aid of an antiserum against a protective protein band (EP-A1-0 283 882); the part-sequence used (amino acids (AA) 631-892 or 630-764) contains at least two T-cell epitopes (Roussilhon et al. (1990), Immunol. Letters 25, 149-154). In preferred embodiments, further T-cell epitope-containing regions of other P. falciparum proteins such as merozoite surface antigen I (MSA I or else "195 kd antigen"), amino acids from 100 to 300, are incorporated (Crisanti et al. (1988), Science 240, 324-326).
    Type: Grant
    Filed: November 16, 1993
    Date of Patent: March 7, 1995
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Bernhard Knapp, Erika Hundt, Burkhard Enders, Hans Kupper
  • Patent number: 5393523
    Abstract: Recombinant histidine-rich protein of Plasmodium falciparum, its preparation and use. It was possible, by screening two different Plasmodium falciparum cDNA gene banks with an antiserum against a 41 kD protein and by cross-hybridization with the insert DNA of a clone obtained therewith, to isolate a gene which codes for a Histidine-Alanine-rich protein (HRP-II). This protein protects aotus monkeys from infection with P. falciparum and is thus a suitable constituent of a malaria vaccine.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: February 28, 1995
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Bernard Knapp, Erika Hundt, Burkhard Enders, Hans Kupper
  • Patent number: 5194587
    Abstract: The invention relates to malaria-specific DNA sequences, to the expression products thereof, and to the use thereof.A combination of three of the expression proteins whose DNA sequences were isolated by screening a lambda gt11 gene bank with a monospecific antiserum against the protective 41kD antigen bend from P. falciparum protects Aotus monkeys completely from a P. falciparum infection in model experiments.
    Type: Grant
    Filed: June 27, 1991
    Date of Patent: March 16, 1993
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Bernhard Knapp, Erika Hundt, Burkhard Enders, Hans Kupper
  • Patent number: 4301142
    Abstract: What is disclosed are a reagent for the detection of infectious mononucleosis by agglutination and a process for its manufacture.
    Type: Grant
    Filed: November 1, 1979
    Date of Patent: November 17, 1981
    Assignee: Behringwerke Aktiengesellschaft
    Inventor: Burkhard Enders
  • Patent number: 4150107
    Abstract: The invention relates to a process for obtaining antigens from living adult schistosomes, wherein schistosomes are kept alive for 12 to 96 hours in a sterile physiologically tolerable salt solution, subsequently isolated and extracted with an aqueous medium, as well as diagnostics for bilharziasis infections containing such antigens or corresponding antibodies and their use for the proof of bilharziasis in vivo and in vitro.
    Type: Grant
    Filed: October 7, 1977
    Date of Patent: April 17, 1979
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Burkhard Enders, Gunter Henke
  • Patent number: 4081241
    Abstract: An in vitro method for the diagnosis of immunization states which involves measuring, in an electric field, the changed mobility of charged indicator particles, other than macrophages, which particles have been treated with (1) a suspension of lymphocytes that have been incubated with an antigen or (2) the cell-free supernatant of such a suspension of incubated lymphocytes.
    Type: Grant
    Filed: August 28, 1975
    Date of Patent: March 28, 1978
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Franz Porzsolt, Christoph Tautz, Rudolf Schmidtberger, Wolfgang Ax, Burkhard Enders